GURU.Markets stock price, segment price, and overall market index valuation
The company's share price BioCardia Inc.
Shares of BioCardia, a biotech company developing cell therapies for heart disease, reflect the sector's binary risks. The price trajectory depends entirely on the results of clinical trials and regulatory decisions regarding its drugs.
Share prices of companies in the market segment - Heart
BioCardia is a biotech company developing cell therapies and delivery devices for the treatment of cardiovascular diseases. We've categorized it as a "Heart" company. The chart below shows how investors value companies working at the intersection of biotech and medical technology in cardiology.
Broad Market Index - GURU.Markets
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. Its innovative approach makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how BioCardia compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
BCDA - Daily change in the company's share price BioCardia Inc.
BioCardia, Inc.'s daily stock price fluctuations reflect the extreme volatility inherent in cell therapy companies. This metric is a measure of the company's sensitivity to clinical trial data from its heart failure drugs.
Daily change in the price of a set of shares in a market segment - Heart
BioCardia develops cell therapies for cardiovascular diseases, operating in the biotech sector, where research news can cause sharp price movements. The chart below is a volatility indicator for the cardiac development segment. It can help you understand whether BCDA price fluctuations are typical for the industry.
Daily change in the price of a broad market stock, index - GURU.Markets
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. Its shares are driven by news of clinical trials. This high volatility is a significant component of the overall "noise" and stock market dynamics.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization BioCardia Inc.
BioCardia, Inc.'s year-over-year performance is a story of developing cell therapies for the treatment of heart disease. Its 12-month market cap is entirely dependent on clinical trial data from its platform for delivering stem cells directly to the heart. Success could lead to a breakthrough in regenerative cardiology.
Annual dynamics of market capitalization of the market segment - Heart
BioCardia, a late-stage biotech company, is developing cell therapies for the treatment of heart disease. Its stock price is entirely dependent on clinical trial results. The chart reflects the enormous potential of its scientific platform and the high risks inherent in this sector.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioCardia, which develops cell therapy for cardiovascular disease, is betting on a breakthrough in medicine. A comparison of its year-over-year market capitalization dynamics with the market demonstrates how expectations for clinical trials and the biotech news cycle can create a unique reality for stocks, distinct from overall economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization BioCardia Inc.
BioCardia is a regenerative medicine company developing cell therapies for the heart. Its monthly performance is entirely dependent on the results of its clinical trials. Data from its flagship programs are binary events, causing sharp fluctuations.
Monthly dynamics of market capitalization of the market segment - Heart
BioCardia, Inc. is a clinical-stage biotherapeutics company developing stem cell-based therapies for cardiovascular diseases. Its sector dynamics, shown in the chart, reflect the risks of R&D. Against this backdrop, one can assess how its unique cell delivery system directly to the heart and its cell therapy are progressing in clinical trials.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
BioCardia is a biotech company developing cell therapy for the heart. Its shares are buoyed by anticipation of clinical trial results. Their monthly performance is completely disconnected from the market, as the chart clearly illustrates, showing a reaction to scientific data rather than general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization BioCardia Inc.
BioCardia develops cell therapy for the treatment of cardiovascular diseases. Its weekly stock price is entirely dependent on the results of clinical trials of this risky but potentially breakthrough therapy.
Weekly dynamics of market capitalization of the market segment - Heart
BioCardia, Inc. develops cell therapies to treat cardiovascular diseases. The chart helps separate the stock's unique reaction to clinical trial news from overall sector sentiment. Is the weekly price movement specific to BioCardia or is it an industry trend?
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
BioCardia, Inc. is a biotech company whose stock moves in sync with clinical trial news. This chart is a great way to see how its weekly fluctuations are disconnected from overall market trends. Is the company living its own life, or is it being affected by the global sell-off?
Market capitalization of the company, segment and market as a whole
BCDA - Market capitalization of the company BioCardia Inc.
The BioCardia chart shows the promise of cell therapy for the heart. The market cap of this company, which is developing stem cell-based therapies for heart failure, reflects investors' faith in its unique delivery system. This is a highly volatile clinical trials curve.
BCDA - Share of the company's market capitalization BioCardia Inc. within the market segment - Heart
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. Its market capitalization in the cardiac drug segment reflects the potential of its unique system for delivering cells directly to the heart muscle. The company's market capitalization reflects the success of its late-stage clinical programs.
Market capitalization of the market segment - Heart
BioCardia is developing cell therapies to treat heart disease. How big is this arena? The chart below shows the overall market capitalization of the cardiac sector. Its dynamics reflect the enormous investment and hopes associated with finding new ways to repair damaged heart muscle.
Market capitalization of all companies included in a broad market index - GURU.Markets
The BioCardia chart shows how the market values cell therapy for heart disease. The company's market cap is based on its system for delivering stem cells directly to the heart. This chart is fraught with clinical risks, but it has the potential to offer a revolutionary treatment for heart failure.
Book value capitalization of the company, segment and market as a whole
BCDA - Book value capitalization of the company BioCardia Inc.
For BioCardia, a cardiac cell therapy company, book value is its tangible foundation: manufacturing contracts, cell delivery systems, and financial reserves for clinical trials. The chart below shows how the company built this scientific and financial foundation.
BCDA - Share of the company's book capitalization BioCardia Inc. within the market segment - Heart
BioCardia, Inc. is a cardiac cell therapy company. Its tangible assets include not only laboratories but also production lines for its unique stem cell delivery systems directly to the myocardium. The chart shows the share of this hybrid (bio + device) medical infrastructure the company controls.
Market segment balance sheet capitalization - Heart
BioCardia is a cell therapy company. The pharmaceutical industry, as the chart shows, is capital-intensive. BioCardia is a prime example. Its business requires the construction of its own highly complex and expensive laboratories and factories.
Book value of all companies included in the broad market index - GURU.Markets
BioCardia's assets are not drugs, but a comprehensive solution for cardiac cell therapy, including both the cells themselves and a system for their precise delivery to the myocardium. Its book value reflects its unique technological and scientific potential in the field of regenerative cardiology.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - BioCardia Inc.
BioCardia is a biotech company developing cell therapies for heart disease. Its value lies in its pipeline and delivery system. The chart shows how the market values its long-standing efforts in this complex field.
Market to book capitalization ratio in a market segment - Heart
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. Its valuation depends on the success of its clinical trials. The chart shows how investors value its unique approach to heart treatment.
Market to book capitalization ratio for the market as a whole
BioCardia develops cell therapies for heart disease. Its market capitalization reflects investor expectations for the success of its treatments. This chart shows how the potential to save lives and improve quality of life in cardiology generates a valuation that exceeds its asset value multiple times.
Debts of the company, segment and market as a whole
BCDA - Company debts BioCardia Inc.
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. Research in this field is extremely expensive and requires lengthy clinical trials. This chart shows how the company raises capital to fund its innovative, but highly capital-intensive, medical research.
Market segment debts - Heart
BioCardia is a late-stage biotech company developing cell therapies for heart disease. This chart shows its financial position at the critical stage of clinical trials, which will determine its future.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio BioCardia Inc.
BioCardia is a biopharmaceutical company specializing in cardiac cell therapy. This chart shows its financial structure. For a company with clinical-stage developments, debt is a significant burden, increasing the risks for investors.
Market segment debt to market segment book capitalization - Heart
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. This is one of the most complex and capital-intensive areas of medicine. The chart shows the overall debt burden in the sector, highlighting the enormous financial resources the company requires to conduct its ambitious research.
Debt to book value of all companies in the market
BioCardia, Inc. is a clinical-stage biopharmaceutical company developing cell therapies for the treatment of heart disease. This is a cutting-edge, but risky, field. This chart clearly shows that the debt market is closed to such companies. Their survival depends on successful clinical data and the ability to attract equity capital.
P/E of the company, segment and market as a whole
P/E - BioCardia Inc.
For BioCardia, a company developing cell therapies for heart disease, the P/E ratio is not applicable. The company has no profit, and its valuation on this chart is arbitrary. It's a bet that its approach to heart muscle regeneration will be successful in clinical trials.
P/E of the market segment - Heart
BioCardia is a clinical-stage regenerative medicine company developing cell therapies for the treatment of cardiovascular diseases. This chart shows the average valuation for the sector, providing investors with context for assessing BioCardia's scientific potential and risks.
P/E of the market as a whole
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. Its valuation is a pure bet on the success of its clinical programs. Overall market sentiment, reflected in this chart, is completely irrelevant. The company's fate depends on the effectiveness of its drugs.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company BioCardia Inc.
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. This chart reflects investor expectations for its clinical trials. The valuation is based on the potential of its procedures to restore heart tissue after a heart attack, a significant medical need.
%20P%2FE%20BioCardia%20Inc.&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-BioCardia-Inc.&v=1772501452814 "Chart of the company's future (projected) P/E BioCardia Inc.")
Future (projected) P/E of the market segment - Heart
BioCardia is a clinical-stage biotech company developing cell therapies for the treatment of cardiovascular diseases. Its valuation relative to other biotechs in the field reflects investors' opinions on its unique therapeutic delivery system, a bet that its approach to heart muscle regeneration will prove successful.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Heart&v=1772501452815 "Future (projected) P/E graph of the market segment - Heart")
Future (projected) P/E of the market as a whole
BioCardia develops cell therapies for the treatment of cardiovascular diseases. The company also produces systems for delivering therapeutic agents directly to the heart. This chart shows the overall risk appetite of investors. For biotech companies working in a complex field like cardiology, a positive market environment is important for funding long-term clinical trials.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772501452815 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit BioCardia Inc.
BioCardia is a biotechnology company developing cell therapies for the treatment of cardiovascular diseases. The financial indicators presented here reflect investments in its unique system for delivering therapy directly to the heart. Success in clinical trials is key to its future.
Profit of companies in the market segment - Heart
BioCardia is a regenerative medicine company developing cell therapies for cardiovascular diseases. This chart shows the overall profitability of the cardiac medicine sector. It helps us understand the potential for cutting-edge methods like cell therapy to become commercially successful in treating the most common diseases.
Overall market profit
BioCardia develops cell therapy for the treatment of cardiovascular diseases. This is an innovative field of medicine. The company's success depends on the results of clinical trials and regulatory approval. The macroeconomic cycles visible in this chart are of little significance for BCDA.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company BioCardia Inc.
BioCardia is a biotechnology company developing cell therapies for the treatment of cardiovascular diseases. Its future profit projections depend on the success of its clinical programs. This chart reflects analyst expectations regarding its developments and their potential in cardiology.
%20profit%20of%20the%20company%20BioCardia%20Inc.&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-BioCardia-Inc.&v=1772501452822 "Graph of future (projected) profit of the company BioCardia Inc.")
Future (predicted) profit of companies in the market segment - Heart
BioCardia is a biotech company developing cell therapies for cardiovascular disease. Their system enables the delivery of stem cells directly to the heart. This graph shows forecasts for the cardiac sector, illustrating the potential of regenerative medicine in treating one of the leading causes of death worldwide.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Heart&v=1772501452824 "Graph of future (predicted) profits of companies in a market segment - Heart")
Future (predicted) profit of the market as a whole
For BioCardia, a company developing cell therapy for heart disease, this chart is an indicator of capital availability. Positive economic expectations facilitate raising funding for expensive clinical trials. A negative market trend could complicate this process.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772501452826 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - BioCardia Inc.
BioCardia is developing cell therapies for the treatment of cardiovascular diseases. This figure, without revenue, is a pure measure of hope. Investors are evaluating the potential of its therapy to restore cardiac function.
P/S market segment - Heart
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. This chart shows the average valuation in the cardiology sector. It reflects investor expectations for BioCardia's potential in regenerative medicine for heart muscle restoration after a heart attack.
P/S of the market as a whole
BioCardia, Inc. is a clinical-stage regenerative medicine company developing cell therapies for the treatment of cardiovascular diseases. The company also manufactures systems for delivering therapies directly to the heart. The company's valuation is based on the potential of this comprehensive approach. This chart helps assess expectations for innovation in cardiology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company BioCardia Inc.
BioCardia develops cell therapies for the treatment of cardiovascular diseases. The company's valuation is based on the future success of its programs. The price reflects investors' belief that its therapies will be able to restore heart tissue and become a valuable tool in cardiology.
%20P%2FS%20BioCardia%20Inc.&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-BioCardia-Inc.&v=1772501452830 "The graph of the company's future (projected) P/S BioCardia Inc.")
Future (projected) P/S of the market segment - Heart
BioCardia is a biotech company developing cell therapies for cardiovascular disease. Its system delivers stem cells directly to the heart. This chart shows how investors view the potential of this innovative approach to treating heart disease.
%20P%2FS%20market%20segment%20graph%20-%20Heart&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Heart&v=1772501452831 "Future (projected) P/S market segment graph - Heart")
Future (projected) P/S of the market as a whole
This chart shows general expectations for the cell therapy market. For BioCardia, a company developing therapies for heart disease, this is an indicator of the investment climate. Market optimism allows it to attract funding for research aimed at restoring heart muscle after a heart attack using stem cells.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772501452831 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales BioCardia Inc.
BioCardia is a clinical-stage regenerative medicine company developing cell therapies for the treatment of cardiovascular diseases. This chart reflects revenue from partnerships and sales of delivery systems. Future revenue is dependent on the success of clinical trials of its therapy aimed at restoring heart muscle after a heart attack.
Sales of companies in the market segment - Heart
BioCardia, Inc. is a clinical-stage biotechnology company developing cell therapies for the treatment of cardiovascular diseases. This chart shows growth in the cardiology sector. BioCardia uses a patient's own cells to regenerate heart muscle after a heart attack, one of the most advanced approaches in regenerative medicine.
Overall market sales
BioCardia, Inc. is a clinical-stage company developing cell therapies for the treatment of cardiovascular diseases. Its market capitalization is dependent on trial results. The overall economic climate, shown in this chart, influences the investment climate and the availability of capital for funding cardiology research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company BioCardia Inc.
BioCardia develops cell therapies for the treatment of cardiovascular diseases. The company also produces delivery systems that deliver therapeutic agents directly to the heart. This graph reflects analysts' expectations for the success of clinical trials in its cardiac programs.
%20sales%20of%20the%20company%20BioCardia%20Inc.&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-BioCardia-Inc.&v=1772501452838 "Schedule of future (projected) sales of the company BioCardia Inc.")
Future (projected) sales of companies in the market segment - Heart
BioCardia is a biotechnology company developing cell therapies for the treatment of cardiovascular diseases. This chart shows expectations for the cardiology sector. It reflects the hopes associated with regenerative medicine, which may offer new ways to restore heart tissue.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Heart&v=1772501452838 "Schedule of future (projected) sales of companies in the market segment - Heart")
Future (projected) sales of the market as a whole
BioCardia, Inc. is a clinical-stage regenerative medicine company developing cell therapies for the treatment of cardiovascular diseases. Its future depends on the success of clinical trials. This graph, reflecting the state of the economy, affects the availability of capital to fund expensive and long-term cardiac research.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772501452841 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality BioCardia Inc.
BioCardia is developing cell therapy for cardiovascular disease. This chart shows the financial status of late-stage clinical trials. Negative values represent investments in completing the research. Success could lead to the development of a first-of-its-kind method for "heart repair."
Market segment marginality - Heart
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. For a company in clinical trials, this chart serves as a benchmark. It shows the average profitability achieved by successful companies in their sector, illustrating the financial potential if their treatments are approved.
Market marginality as a whole
BioCardia is a biopharmaceutical company developing cell therapies for the treatment of cardiovascular diseases. This overall market profitability chart is irrelevant to the company. Its future depends solely on the results of clinical trials and the ability to prove that its approach can help patients with heart disease.
Employees in the company, segment and market as a whole
Number of employees in the company BioCardia Inc.
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. This graphic shows a small team advancing their research through clinical trials using unique delivery systems.
Share of the company's employees BioCardia Inc. within the market segment - Heart
BioCardia, Inc. develops cell therapies to treat cardiovascular diseases by delivering cells directly to the heart. This chart shows the percentage of cardiologists, cell therapy specialists, and biomedical engineers the company attracts in this niche field. It reflects its unique concentration of expertise in treating the heart at the cellular level.
Number of employees in the market segment - Heart
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. Delivering stem cells directly to the heart is an innovative approach. This graph illustrates how regenerative medicine seeks to restore damaged organs, requiring unique equipment and a team of cardiac surgeons and biologists.
Number of employees in the market as a whole
BioCardia, Inc. is developing cell therapies for the treatment of heart disease, one of the most pressing challenges in medicine. This graph reflects the scale of the healthcare sector, where cardiovascular disease is a major challenge. BioCardia's innovations can not only save lives but also create new standards of treatment, requiring new specialists.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company BioCardia Inc. (BCDA)
BioCardia is a biotech company developing cell therapies for cardiovascular diseases. This chart represents the net intellectual capital valuation. The company's value is based on its therapeutic platform and delivery systems. The chart shows how highly the market values this scientific potential in cardiac treatment per scientist.
%20of%20the%20company%20BioCardia%20Inc.%20(BCDA)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-BioCardia-Inc.-BCDA&v=1772501452861 "Chart of market capitalization per employee (in thousands of dollars) of the company BioCardia Inc. (BCDA)")
Market capitalization per employee (in thousands of dollars) in the market segment - Heart
BioCardia develops cell therapies for the treatment of cardiovascular diseases, one of the most complex and important areas of medicine. This chart shows the investors' bets on their scientific team and unique cell delivery methods. It evaluates the life-saving potential of their technology.
%20by%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Heart&v=1772501452862 "Market capitalization per employee (in thousands of dollars) by market segment - Heart")
Market capitalization per employee (in thousands of dollars) for the overall market
BioCardia, Inc. is a biotechnology company developing cell therapies for the treatment of cardiovascular diseases. This chart shows the market-wide per-employee performance metric, highlighting the market's hopes for a breakthrough in cardiology.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772501452864 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company BioCardia Inc. (BCDA)
BioCardia is a clinical-stage biotech company focused on treating heart disease. The company has no commercial products. This chart shows the net loss per employee. It reflects how much the company "burns" per scientist.
%20Chart%20BioCardia%20Inc.%20(BCDA)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-BioCardia-Inc.-BCDA&v=1772501452870 "Company Profit Per Employee (in thousands of dollars) Chart BioCardia Inc. (BCDA)")
Profit per employee (in thousands of dollars) in the market segment - Heart
BioCardia, Inc. is a company developing cell therapies for the treatment of cardiovascular diseases. Its business is focused on clinical research. The negative earnings per employee, which this chart likely shows, is standard for the biotech industry and reflects significant investment in the scientific team in anticipation of product approval and launch.
%20in%20the%20market%20segment%20-%20Heart&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Heart&v=1772501452871 "Chart of profit per employee (in thousands of dollars) in the market segment - Heart")
Profit per employee (in thousands of dollars) for the market as a whole
BioCardia (BCDA) is a clinical-stage biotech company developing cell therapy (stem cells from a patient's bone marrow) for the treatment of heart failure. It's an R&D business. This chart shows the market average dollar return per employee. For BCDA (which is not yet profitable), this is a benchmark: in biotech, IP can significantly exceed this average.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772501452872 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee BioCardia Inc. (BCDA)
BioCardia is a biotech company developing cell therapies for the treatment of cardiovascular diseases. This chart reflects the hopes of regenerative medicine. The current low values are typical for biotech, but they could change dramatically if clinical trials are successful.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-BioCardia-Inc.-BCDA&v=1772501452874 "Sales chart per company employee BioCardia Inc. (BCDA)")
Sales per employee in the market segment - Heart
BioCardia is a biotechnology company developing cell therapies for the treatment of cardiovascular diseases. The company is in the R&D stage. This chart shows the average revenue per employee in this segment. It serves as a productivity benchmark for commercial pharmaceutical companies and helps evaluate the effectiveness of BioCardia's scientific team.
Sales per employee for the market as a whole
BioCardia is a biotech company developing cell therapies for cardiovascular diseases, as well as delivery devices. The company has no commercial revenue, which is irrelevant. Its entire value lies in the potential of its R&D team.
Short shares by company, segment and market as a whole
Shares shorted by company BioCardia Inc. (BCDA)
BioCardia is a biotech company developing cell therapy (stem cells) that is injected directly into the heart to treat heart failure. It's an extremely risky procedure. This chart shows the odds that their therapy won't work or will be too dangerous for the company to receive FDA approval.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-BioCardia-Inc.-BCDA&v=1772501452876 "Short Shares Chart for the Company BioCardia Inc. (BCDA)")
Shares shorted by market segment - Heart
BioCardia, Inc. (BCDA) is a biotech company developing cell therapies to treat cardiovascular disease (heart failure) by delivering cells directly to the heart. This chart reflects the total short position in the cell therapy sector. High values indicate general investor skepticism about the success of clinical trials in cardiology.
Shares shorted by the overall market
BioCardia (BCDA) is a clinical-stage biotech company. Its value is based on future expectations. When this market fear indicator rises, investors' risk appetite evaporates. They are the first to sell speculative, unprofitable biotechs like BCDA in favor of safer assets.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator BioCardia Inc. (BCDA)
BioCardia (BCDA) is a biotech company developing cell therapies for heart failure. They also have a unique system for delivering drugs directly to the heart. This oscillator measures momentum. It shows when the stock is "overheated" (above 70) pending trial data or "oversold" (below 30) amid delays.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-BioCardia-Inc.-BCDA&v=1772501452878 "RSI 14 indicator chart for the company's stock BioCardia Inc. (BCDA)")
RSI 14 Market Segment - Heart
BioCardia is a biotech company developing cell therapies for cardiovascular disease. Its approach involves delivering stem cells directly to the heart. This chart tracks the collective momentum of the cardiovascular biotech sector. It helps understand whether the BCDA trend is a response to its drugs or part of a broader sector trend.
RSI 14 for the overall market
BioCardia (BCDA) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast BCDA (BioCardia Inc.)
BioCardia is a biotech company developing a cell therapy (CardiAMP) for the treatment of heart failure. The company also manufactures therapy delivery systems. This chart shows the average analyst forecast. Their targets are based on the results of key clinical trials and the regulatory prospects for this therapy.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-BCDA-BioCardia-Inc.&v=1772501452881 "A chart showing analyst consensus forecasts for the expected stock price. BCDA (BioCardia Inc.)")
The difference between the consensus estimate and the actual stock price BCDA (BioCardia Inc.)
BioCardia is a biotech company that delivers stem cells (taken from the patient) directly to the heart to treat heart failure. This chart measures the gap between the current price and the consensus target price. It shows how much confidence experts have in this breakthrough, yet complex, cardiac therapy.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-BCDA-BioCardia-Inc.&v=1772501452882 "A chart showing the difference between the consensus forecast and the actual stock price. BCDA (BioCardia Inc.)")
Analyst consensus forecast for stock prices by market segment - Heart
BioCardia is a biotech company developing stem cell-based therapies and a delivery system (Helix) for the treatment of heart failure. This chart shows general expectations for the cardiology sector. It reflects whether experts believe in cardiac "regeneration" using stem cells.
Analysts' consensus forecast for the overall market share price
BioCardia (BCDA) is a company that "repairs the heart" with cells. They develop cell therapies and devices (Helix) that deliver a patient's stem cells directly to the heart muscle. This chart shows the overall risk appetite. It reflects the market's willingness to fund breakthrough, but extremely expensive, R&D projects.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index BioCardia Inc.
BioCardia is a heart repair company. It's a biotech company that uses stem cells (taken from a patient's own bone marrow) and a special catheter (Helix) to deliver them directly into the heart to treat heart failure. This graph is a pure indicator of their R&D. It reflects their (very long) journey and their risky bet.
AKIMA Market Segment Index - Heart
BioCardia (BCDA) uses cell therapy to repair the heart. The company develops both the stem cells themselves and a patented catheter (Helix) for their precise delivery to damaged heart muscle. This chart shows the average index for the segment. It helps assess how this combo strategy (cells + device) compares to the average market.
The AKIM Index for the overall market
BioCardia is a company developing cell therapies for heart failure and a delivery system (Helix). This chart, which reflects the market average, provides a macro backdrop. It helps assess how BCDA, a regenerative cardiac medicine company, compares to overall economic trends.
